SCHEMBL2383446

SCHEMBL2383446

CC(C)(C)c1ccc(OCc2ccccc2)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.54
RXRA P19793 2/20 0.52
RXRB P28702 2/20 0.52
RXRG P48443 2/20 0.52
EGFR P00533 2/20 0.49
MAOB P27338 3/20 0.48
SRC P12931 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LIPE Q05469 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383267 0.88 MRGPRX4 (0.51) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL10390879 0.85 TDP1 (0.46) MRGPRX4RXRARXRBRXRGEGFR
SCHEMBL19483249 0.85 MRGPRX4 (0.55) MRGPRX4RXRARXRBRXRGTDP1
SCHEMBL12295554 0.84 MRGPRX4 (0.68) MRGPRX4RXRARXRBRXRGTDP1
SCHEMBL12772068 0.83 MRGPRX4 (0.52) MRGPRX4RXRARXRBRXRGTDP1
SCHEMBL29951292 0.82 LIPE (0.62) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL15674928 0.82 LIPE (0.62) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL768907 0.82 MRGPRX4 (0.52) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL24314204 0.81 FFAR1 (0.52) MRGPRX4RXRARXRBRXRGTDP1
SCHEMBL19728976 0.81 RXRA (0.71) MRGPRX4RXRARXRBRXRGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 MRGPRX4 2299/4885RXRA 137/4885RXRB 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.